Bob Lapetina - Jan 2, 2024 Form 3 Insider Report for Immunome Inc. (IMNM)

Role
PAO and VP Finance & Corporate
Signature
/s/ Sandra Stoneman, Attorney-in-fact
Stock symbol
IMNM
Transactions as of
Jan 2, 2024
Transactions value $
$0
Form type
3
Date filed
1/4/2024, 05:40 PM

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding IMNM Common Stock 12K Jan 2, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding IMNM Stock option (right to buy) Jan 2, 2024 Common Stock 11K $16.59 Direct F1
holding IMNM Stock option (right to buy) Jan 2, 2024 Common Stock 300 $20.92 Direct F2
holding IMNM Stock option (right to buy) Jan 2, 2024 Common Stock 12K $3.42 Direct F3
holding IMNM Stock option (right to buy) Jan 2, 2024 Common Stock 17.6K $4.84 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the options vest on May 12, 2022, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter.
F2 25% of the shares subject to the options vest on May 28, 2022, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter.
F3 25% of the shares subject to the options vest on May 27, 2023, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter.
F4 25% of the shares subject to the options vest on June 8, 2024, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter.

Remarks:

See Attached Exhibit 24